Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
Pentoxifylline offers a well-tolerated and effective alternative to the treatment options available for patients with peripheral vascular disease and in isolated studies proved to be superior to drugs such as co-dergocrine mesylate, adenosine and pyrithioxine. Expand
Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
The promising clinical response of patients with various forms of candidiasis or cryptococcosis--together with convenient administration regimens--recommends fluconazole as a useful addition to currently available systemic antifungal therapies, in particular for the treatment of mycoses in patients with AIDS. Expand
Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Transdermal hyoscine may offer an effective and conveniently administered alternative for the prevention of motion-induced nausea and vomiting in certain situations, but the duration of its clinical effectiveness, and its relative efficacy and tolerability compared with other agents needs to be confirmed. Expand
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
Overall, available data appear to indicate that while the efficacy of paroxetine is similar to that of traditional antidepressant drugs, the newer agent possesses much improved tolerability and may be beneficial when treating patients with an increased risk of suicide. Expand
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Although treatment with foscarnet produces some severe adverse effects, with care these can be minimised, and the drug produces clinical improvement in a large proportion of patients; this is a highly encouraging finding at this stage in its development. Expand
Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
Preliminary findings indicate that itraconazole may hold promise for the prophylaxis of opportunistic fungal infections in patients at risk, for example women with chronic recurrent vaginal candidiasis, immunodeficient patients with chronic mucocutaneous candidiasis and patients receiving immunosuppressant drugs. Expand
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Clinical efficacy and promising in vitro and preliminary in vivo activity of clarithromycin against Mycobacterium leprae and Helicobacter pylori warrant further clinical trials to assess its efficacy in patients with these infections. Expand
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
Flutamide is a suitable alternative to other systemic treatment in patients with advanced prostatic cancer who wish to preserve sexual potency and in combination with an LHRH agonist flutamide may become a first-line agent for previously untreated patients with cancer of the prostate. Expand
Paracetamol and Phenacetin
- S. Clissold
The pre-eminent position of paracetamol and aspirin as the non-narcotic analgesic agents of choice for mild to moderate pain is being seriously challenged by ‘newer’ non-steroidal anti-inflammatory drugs. Expand
Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study
MSS progresses despite treatment with currently available antispastic agents, and it is associated with a high level of disability, and spasticity treatment represents a minor element of the overall cost of managing MSS patients in Spain. Expand